Status:
WITHDRAWN
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
Lead Sponsor:
Eli Lilly and Company
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to investigate the efficacy and safety of Volenrelaxin in adults with Chronic Kidney Disease. The study will last about 24 weeks.
Eligibility Criteria
Inclusion
- Have a diagnosis of Chronic Kidney Disease (CKD) based on eGFR category and albuminuria category per the Kidney Disease: Improving Global Outcomes (KDIGO) criteria
- Have been on a maximally tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) for 90 days preceding screening and is expected to remain on a stable regimen through the study
- If on additional treatment for CKD, must be on stable dose for at least 90 days before screening.
- If diagnosed with Type 2 Diabetes, should be on stable antihyperglycemic treatment for at least 90 days before screening.
Exclusion
- Have any one of the following cardiovascular conditions 90 days prior to screening:
- myocardial infarction
- stroke
- hospitalization or urgent visit for heart failure, and
- coronary, carotid, or peripheral artery revascularization.
- Have a documented New York Heart Association (NYHA) Class IV heart failure at the time of screening.
- Have chronic or intermittent hemodialysis or peritoneal dialysis 90 days prior to screening.
- Have acute dialysis or acute kidney injury 90 days prior to screening.
- Have a history of a congenital or hereditary kidney disease, polycystic kidney disease, lupus nephritis, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and nephrotic syndrome
- Requires chronic immunosuppression.
- Have HbA1c \>8.5% at screening
- Have had a transplanted organ or are awaiting an organ transplant
- Have a diagnosis or history of malignant disease within 5 years prior to baseline.
- Have symptomatic hypotension.
- Have acute or chronic hepatitis.
Key Trial Info
Start Date :
October 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06598631
Start Date
October 9 2024
End Date
December 30 2024
Last Update
October 2 2025
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Rancho Research Institute
Downey, California, United States, 90242
2
Southwest Nephrology Associates
Evergreen Park, Illinois, United States, 60805
3
Nephrology Associates of Northern Illinois and Indiana (NANI) - Hinsdale
Hinsdale, Illinois, United States, 60521
4
Nephrology Associates of Northern Illinois and Indiana (NANI) - Huntley
Huntley, Illinois, United States, 60142